New hope for anemia in CLL patients: acalabrutinib trial shows promise
NCT ID NCT04657094
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tests a drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) who also have a type of anemia where the immune system attacks red blood cells. The goal is to see if the drug can control the anemia after other treatments have failed. Only 4 people took part, and they received acalabrutinib to block certain enzymes that help cancer grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.